Boussard & Gavaudan Investment Management LLP Acquires New Position in Insulet Co. (NASDAQ:PODD)

Boussard & Gavaudan Investment Management LLP purchased a new position in shares of Insulet Co. (NASDAQ:PODD) during the 4th quarter, HoldingsChannel reports. The firm purchased 7,732 shares of the medical instruments supplier’s stock, valued at approximately $2,036,000.

A number of other hedge funds also recently bought and sold shares of PODD. SBI Securities Co. Ltd. acquired a new position in shares of Insulet during the fourth quarter worth about $36,000. SRS Capital Advisors Inc. lifted its stake in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 56 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares in the last quarter. Friedenthal Financial purchased a new stake in shares of Insulet in the 4th quarter valued at approximately $57,000. Finally, Assetmark Inc. raised its holdings in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 246 shares in the last quarter.

Insulet Stock Performance

NASDAQ:PODD opened at $260.27 on Friday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The firm’s fifty day simple moving average is $272.03 and its 200-day simple moving average is $258.25. The stock has a market cap of $18.28 billion, a PE ratio of 44.95, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. Analysts expect that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insider Activity at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now directly owns 3,231 shares of the company’s stock, valued at $888,525. This trade represents a 36.10 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. upped their price objective on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Wells Fargo & Company upped their price target on Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a report on Friday, February 21st. TD Cowen increased their price target on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. StockNews.com downgraded shares of Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Finally, Canaccord Genuity Group increased their target price on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.